Showing 5111-5120 of 5693 results for "".
- Potent affronEYE Saffron Extract May Lower Risk of Glaucomahttps://modernod.com/news/potent-affroneye-saffron-extract-may-lower-risk-of-glaucoma/2477259/A new animal study suggests affronEYE saffron could help prevent the onset of glaucoma. The antioxidant and anti-inflammatory characteristics of this potent saffron extract, developed by Pharmactive Biotech Products, S.L., demonstrated an ability to protect retinal cells from damage and death and
- Clearwave Launches New Patient Interface Solutionhttps://modernod.com/news/clearwave-launches-new-patient-interface-solution/2477249/Clearwave, a provider of patient check-in solutions via mobile, kiosk, and desktop, announced the launch of Clearwave Connect, a new tablet-based application to enhance front-office experiences. With Clearwave Connect, practices will have the ability to improve check-in speed and accessibility wi
- FDA Accepting Less Data, More Surrogate Endpoints in Trialshttps://modernod.com/news/fda-accepting-less-data-more-surrogate-endpoints-in-trials/2477241/Over the last four decades, the FDA has loosened its requirements for approving new drugs, increasingly accepting less data and more surrogate endpoints in clinical trials, and shortening its reviews, according to a new analysis, as reported</
- Bausch + Lomb Secures Additional Approvals of Vyzulta in Hong Kong and Argentinahttps://modernod.com/news/bausch-lomb-secures-additional-approvals-of-vyzulta-in-hong-kong-and-argentina/2477234/Nicox announced that its partner, Bausch + Lomb, has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Hong Kong and Argentina. With these approvals, Vyzulta is now approved for commercialization in a total of five countries and territories. Vyzulta is indi
- Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-for-dry-eye-disease/2477235/Neuroptika announced that the first patient was enrolled in a phase 2 clinical trial of NRO-1 for the treatment of dry eye disease. NRO-1 is a novel therapeutic with the potential to protect and regenerate corneal nerves in ophthalmic diseases. “Existing treatments for dry eye diseas
- Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma’s Impact on Daily Livinghttps://modernod.com/news/allergan-teams-up-with-super-bowl-mvp-von-miller-to-raise-awareness-of-glaucomas-impact-on-daily-living/2477236/Allergan announced a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker, and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the ‘My Glaucoma’ campaign, Mr. Miller wil
- IrisVision and Samsung Announce Partnership to Roll Out Vision Correction Software Platformhttps://modernod.com/news/irisvision-and-samsung-announce-partnership-to-roll-out-vision-correction-software-platform/2477229/Samsung Electronics and IrisVision announced a strategic partnership to roll out IrisVision’s technology worldwide. IrisVision’s vision correction software platform utilizes the power of Samsung’s industry leading Galaxy smartphones and XR devices and mobile AI platform to enable people
- Bionic Vision Technologies Announces Interim Pilot Study Results of the BVT Bionic Eye Systemhttps://modernod.com/news/bionic-vision-technologies-announces-interim-pilot-study-results-of-the-bvt-bionic-eye-system/2477228/Bionic Vision Technologies announced interim results of a pilot study involving 4 patients with late-stage retinitis pigmentosa (RP) implanted with a visual prosthesis designed to improve awareness of external objects
- Improved Reimbursement for Endoscopic Cyclophotocoagulation (ECP) when Combined with Cataract Surgeryhttps://modernod.com/news/improved-reimbursement-for-endoscopic-cyclophotocoagulation-ecp-when-combined-with-cataract-surgery/2477219/Beaver-Visitec International (BVI) expressed support for two new CPT codes and improved reimbursement for ECP when combined with cataract surgery. Up to 1 in 5 patients [1] undergoing cataract extraction suffers from glaucoma, and ECP remains an important option for ophtha
- Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry AMDhttps://modernod.com/news/gemini-therapeutics-enrolls-first-patient-in-phase-1-study-of-gem103-for-dry-amd/2477214/Gemini Therapeutics announced it has initiated enrollment in its phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of